Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Rhea-AI Summary
Allogene Therapeutics (Nasdaq: ALLO) closed an underwritten public offering on April 16, 2026, selling 87,500,000 shares at $2.00 per share and 12,700,000 additional shares from the underwriters' option, raising $200.4 million in aggregate gross proceeds before fees.
Allogene expects to use net proceeds for general corporate purposes, which may include clinical trial expenses, research and development, general and administrative costs, and capital expenditures. The offering was completed off a shelf registration declared effective April 25, 2024, and a final prospectus supplement was filed with the SEC.
Positive
- $200.4 million gross proceeds from the offering
- Provides cash for clinical trial and R&D expenses
- Offered under a shelf registration effective April 25, 2024
Negative
- Issued 100.2 million shares (including option exercise), likely dilutive to existing shareholders
- Net proceeds will be reduced by underwriting discounts, commissions, and offering expenses
News Market Reaction – ALLO
In the Apr 17 session, ALLO gained 0.84%, reflecting a mild positive market reaction. Argus tracked a peak move of +9.2% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Offering priced | Negative | -4.8% | Pricing of 87.5M-share common stock offering at $2.00 per share. |
| Apr 13 | Offering proposed | Negative | -25.5% | Proposed $175M common stock sale with additional underwriter option. |
| May 13 | Offering priced | Negative | +2.1% | Pricing of $110M common stock offering at $2.90 per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
For prior common stock offerings, ALLO’s average 1-day move was -9.41%, suggesting a history of pressure around equity raises.
Over the past year, Allogene has repeatedly accessed the equity markets, including a $110M common stock offering in May 2024 and successive proposed and priced offerings in April 2026. These raises were targeted to fund clinical trial and R&D activities. Price reactions to these offering announcements were generally negative, with one modest positive outlier, indicating that dilution concerns often weighed on the stock when new equity was issued.
Key Terms
underwritten public offering financial
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of
Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures.
Goldman Sachs & Co. LLC, Jefferies and TD Cowen acted as joint bookrunners for the offering. Piper Sandler and William Blair also acted as joint bookrunners for the offering. Baird and Canaccord Genuity acted as lead managers for the offering. TPG Capital BD, LLC acted as co-manager for the offering.
The shares of common stock described above were offered by Allogene pursuant to a shelf registration statement filed by Allogene with the Securities and Exchange Commission (SEC) that was declared effective on April 25, 2024. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at (877) 821-7388, or by emailing prospectus_department@jefferies.com; or from TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Allogene’s expectations with respect to the use of proceeds from the offering. For such statements, Allogene claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Allogene’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, those factors disclosed in Allogene’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, and other filings that Allogene may make from time to time with the SEC. These forward-looking statements represent Allogene’s judgment as of the time of this release. Allogene disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
